Juan Torres Melero

Dr. Juan Torres Melero


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
IMIsrael Manzanedo
Israel Manzanedo
FPFernando Pereira
Fernando Pereira
PCPedro Antonio Cascales-Campos
Pedro Antonio Cascales-Campos
FCFrancisco Cristóbal Muñoz Casares
Francisco Cristóbal Muñoz Casares
EDEnrique Asensio Díaz
Enrique Asensio Díaz
RGREGECOP Group
REGECOP Group
Introduction: Treatment of Peritoneal Surface Malignancies (PSM) with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has achieved results never seen before in these patients, which classically have a poor prognosis. The possibility of conducting clinical trials in these diseases is complicated, since some of them are rare, so the analysis of large databases provides very valuable scientific information. The aim of this study is to analyze the global results of the National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP), whose objective is to register all patients scheduled for HIPEC nationwide. Methods: This is a retrospective analysis of the data recorded in the REGECOP from 36 Spanish hospitals from 2001 to 2021. There were 4159 surgical interventions in 3980 patients. Results: 66% are women and 34% are men with a median age of 59 years (range 17–86). 41.5% of the patients were treated for Peritoneal Metastases (PM) of colorectal cancer (CRC); 32.4% were women with ovarian cancer (OC) with PM; 12.8% were treated for pseudomyxoma peritonei (PMP); 6.2% had PM from gastric cancer (GC); 4.9% had PM of non-conventional origin; and, finally, 2.1% of cases were patients diagnosed with peritoneal mesothelioma. The median Peritoneal Cancer Index (PCI) was 9 (0–39), and complete cytoreduction was achieved in 81.7% of the procedures. Severe morbidity (Dindo–Clavien grade III–IV) was observed in 17.7% of surgeries, with 2.1% mortality. Median hospital stay was 11 days (0–259). Median overall survival (OS) was 41 months for CRC patients, 55 months for women with OC, was not reached in PMP patients, was 14 months for GC patients, and 66 months in mesothelioma patients. Conclusions: large databases provide extremely useful data. CRS with HIPEC in referral centers is a safe treatment with encouraging oncologic results in PSM.

1 February 2018 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
RMRafael Morales-Soriano
Rafael Morales-Soriano
NENeus Esteve-Pérez
Neus Esteve-Pérez
Juan José Segura-SampedroJuan José Segura-Sampedro
Juan José Segura-Sampedro
PCPedro Cascales-Campos
Pedro Cascales-Campos
PBPedro Barrios
Pedro Barrios
JVJ. Vaqué-Urbaneja
J. Vaqué-Urbaneja

25 July 2024 in Cancers
Verified
Journal Article
Open access
PDF file
FCFrancisco Cristóbal Muñoz Casares
Francisco Cristóbal Muñoz Casares
Javier Martin-BrotoJavier Martin-Broto
Javier Martin-Broto
PCPedro Antonio Cascales-Campos
Pedro Antonio Cascales-Campos
JMJuan Torres Melero
Juan Torres Melero
ILIrene López-Rojo
Irene López-Rojo
JAJosé Manuel Asencio
José Manuel Asencio
Peritoneal sarcomatosis is a rare malignant disease with a poor prognosis, secondary to peritoneal dissemination of abdominopelvic soft tissue sarcomas. Its rarity, together with the characteristic histological heterogeneity and the historically poor response to systemic treatments, has prevented the establishment of widely accepted treatment criteria with curative intent. In this sense, radical cytoreductive surgery (CRS) with peritonectomy procedures and hyperthermic intraperitoneal chemotherapy (HIPEC), widely used in peritoneal carcinomatosis with excellent results, have not had the same evolutionary development in patients with peritoneal sarcomatosis. A multidisciplinary working group of experts in sarcomas and peritoneal oncological surgery established a series of recommendations based on current scientific evidence for the management of peritoneal sarcomatosis, taking into account the different histological subgroups of abdominopelvic sarcomas that can cause it depending on their origin: retroperitoneal sarcomas, uterine sarcomas, and visceral/peritoneal sarcomas of GIST (gastrointestinal stromal tumor) and non-GIST origin. This article shows the results of sarcoma experts’ voting on the recommendations presented during the I Ibero-American Consensus on the Management of Peritoneal Sarcomatosis, which took place during the recent celebration of the III Hispanic-Portuguese Meeting for Updates on the Treatment of Sarcomas.